IRIS
VITA, GIANLUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.396
NA - Nord America 5.622
AS - Asia 4.303
SA - Sud America 1.367
AF - Africa 130
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 11
Totale 18.842
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.475
RU - Federazione Russa 3.823
SG - Singapore 1.958
BR - Brasile 1.171
CN - Cina 1.151
IE - Irlanda 902
SE - Svezia 603
IT - Italia 587
HK - Hong Kong 384
PL - Polonia 333
DE - Germania 288
FR - Francia 282
VN - Vietnam 282
FI - Finlandia 178
GB - Regno Unito 160
IN - India 128
UA - Ucraina 81
BD - Bangladesh 80
AR - Argentina 76
CA - Canada 59
MX - Messico 56
TR - Turchia 45
IQ - Iraq 43
ZA - Sudafrica 38
ID - Indonesia 36
BE - Belgio 32
AT - Austria 30
EC - Ecuador 30
CI - Costa d'Avorio 28
JP - Giappone 28
NL - Olanda 24
VE - Venezuela 22
PK - Pakistan 21
CO - Colombia 20
MA - Marocco 19
CL - Cile 16
ES - Italia 15
KE - Kenya 15
UZ - Uzbekistan 15
LT - Lituania 13
MY - Malesia 13
PH - Filippine 13
SA - Arabia Saudita 13
CZ - Repubblica Ceca 12
AE - Emirati Arabi Uniti 10
JO - Giordania 10
PE - Perù 10
PY - Paraguay 10
TN - Tunisia 10
EU - Europa 9
AZ - Azerbaigian 8
IL - Israele 8
KZ - Kazakistan 8
NP - Nepal 8
AU - Australia 7
CR - Costa Rica 7
EG - Egitto 7
JM - Giamaica 7
UY - Uruguay 6
DO - Repubblica Dominicana 5
OM - Oman 5
RO - Romania 5
KW - Kuwait 4
NZ - Nuova Zelanda 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
BO - Bolivia 3
BY - Bielorussia 3
CY - Cipro 3
GY - Guiana 3
HU - Ungheria 3
IR - Iran 3
KR - Corea 3
LB - Libano 3
NI - Nicaragua 3
TH - Thailandia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AO - Angola 2
GA - Gabon 2
HN - Honduras 2
KG - Kirghizistan 2
LK - Sri Lanka 2
MD - Moldavia 2
PS - Palestinian Territory 2
RS - Serbia 2
SN - Senegal 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CH - Svizzera 1
DK - Danimarca 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
Totale 18.821
Salva come PNG Salva come JPEG
Città #
Moscow 1.121
Ashburn 946
Dublin 901
Singapore 813
Chandler 615
Dallas 588
Beijing 426
Hong Kong 384
Nyköping 377
Warsaw 321
San Jose 277
Jacksonville 237
The Dalles 220
Princeton 175
Messina 147
Medford 140
Lauterbourg 137
Ann Arbor 135
Los Angeles 128
Cambridge 114
Ho Chi Minh City 100
New York 97
Munich 92
Des Moines 91
São Paulo 81
Buffalo 65
Boardman 63
Council Bluffs 62
Dearborn 62
Lancaster 59
Bremen 58
Tianjin 58
Shenyang 57
Pune 53
San Mateo 49
Turku 47
Frankfurt am Main 46
Orem 46
Hanoi 44
Wilmington 43
Jinan 42
Rio de Janeiro 42
Redondo Beach 41
Rome 39
Houston 36
Belo Horizonte 32
Nanjing 31
Brussels 30
Abidjan 28
Guangzhou 28
Tokyo 25
Chennai 24
Brooklyn 23
Hebei 23
Porto Alegre 23
Curitiba 22
Hangzhou 22
Helsinki 22
Milan 22
Ningbo 22
Santa Clara 22
Brasília 21
Zhengzhou 21
Atlanta 20
Dong Ket 20
Baghdad 19
Amsterdam 17
Montreal 17
Toronto 17
London 16
Johannesburg 15
Stockholm 15
Woodbridge 15
Catania 14
Jakarta 14
Nuremberg 14
Salvador 14
Seattle 14
Shanghai 14
Tashkent 14
Vienna 14
Changsha 13
Manchester 13
Mexico City 13
Palo Del Colle 13
Taizhou 13
Denver 12
Guarulhos 12
Nanchang 12
Quito 12
Chicago 11
Dhaka 11
Haikou 11
Hyderabad 11
Istanbul 11
Juiz de Fora 11
Nairobi 11
Norwalk 11
Phoenix 11
Poplar 11
Totale 10.622
Salva come PNG Salva come JPEG
Nome #
6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR) 329
Psychosocial impact of presymptomatic genetic testing for amyloidotic polyneuropathy 285
Psychosocial impact of presymptomatic genetic testing for amyloidotic polyneuropathy 258
A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy 251
Clinical and pathological features of focal myositis 248
Circulating miRNAs expression as potential biomarkers of mild traumatic brain injury 219
Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis 216
24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. 210
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study 199
Which are the factors influencing NIV adaptation and tolerance in ALS patients? 198
microRNA-10 and -221 modulate differential expression of Hippo signaling pathway in human astroglial tumors 198
Anabolic treatment with RHPTH of duchenne muscular dystrophy related osteoporosis: a case report 195
Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in Mdx mice 194
Effect of exercise on telomere length and telomere proteins expression in mdx mice 188
Autonomic nervous system involvement in spinal muscular atrophy. 187
Hippo signaling pathway is altered in Duchenne muscular dystrophy 187
Nusinersen versus sham control in later-onset spinal muscular atrophy 186
ANT1 is reduced in sporadic inclusion body myositis. 177
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 176
Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy 176
Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center 175
6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes 171
ANT1 expression and RAGE-NF-kB pathway in sporadic inclusion body myositis. 169
Pilot study of flavocoxid in ambulant DMD patients. 169
Pilot study of serial casting of ankles in muscular dystrophy patients. 167
Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies 167
Neuropsychological patter in centronuclear myopathy due to DNM2 gene mutations. 166
Pilot study of serial casting in muscular dystrophy patients. 165
Modulation of neural nitric oxide synthase by the isoflavone genistein promotes muscle regeneration in mdx mice 164
Emergenze respiratorie nelle malattie neurologiche 164
Parenteral nutrition improves nutritional status, autonomic symptoms and qol in patients with TTR-FAP 161
Predictors of adaptation to non-invasive ventilation in amyotrophic lateral sclerosis 160
Impaired myocardial deformation revealing subclinical left ventricular dysfunction in children with Duchenne dystrophy: a speckle tracking echocardiography study 156
Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates 156
Predictors of adaptation to non-invasive ventilation in neuromuscular disorders. 155
Psycological status and emotional burden in amyotrophic lateral sclerosis caregivers: the role of metacognitive processes. 154
Dolori muscolari, deficit di forza e/o disturbi sensitivi 154
Psychosocial impact of sport activity in neuromuscular disorders 154
Impaired myocardial strain in early stage of Duchenne muscular dystrophy: its relation with age and motor performance 154
The 24-month PUL changes and steroids correlation. 153
Novel outcome measures for Charcot-Marie-Tooth disease: Validation and reliability of the 6-min walk test and StepWatch™ Activity Monitor and identification of the walking features related to higher quality of life 152
Pilot study of flavocoxid in ambulant DMD patients. 150
Outcome measures in Duchenne muscular dystrophy: validation of the Pediatric Quality of Life InventoryTM Neuromuscular Module in the Italian population and correlation with other functional assessments. 150
Pilot study of flavocoxid in ambulant DMD patients. 150
BONE INVOLVEMENT IN DUCHENNE MUSCULAR DYSTROPHY 149
Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age 149
Severe rhabdomyolysis in a patient with “Heat Stroke” 148
ANT1 expression and RAGE-NF-kB pathway in sporadic inclusion body myositis 147
Burden, social network and professional support in the families of patients with muscular dystrophies: results from the GUP10002 study. 146
Burden, professional support, and social network in families of children and young adults with muscular dystrophies 146
Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy 145
Clinical variability in spinal muscular atrophy type III 144
Impaired rotational mechanics and strain revealing subclinical left ventricular dysfunction in children with Duchenne muscular dystrophy: a skeckle tracking study. 143
Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes 142
Sport activity in Charcot-Marie-Tooth disease: A case study of a Paralympic swimmer 142
Telomere shortening and telomere-associated proteins in Duchenne muscular dystrophy. 141
Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy 141
First report of a family with a DMD out of frame exon 2 deletion associated with asymptomatic phenotypes. 141
Teriparatide (rhPTH 1-34) in Duchenne Muscular Dystrophy related osteoporosis: a case report. 140
Cardiac function in types II and III spinal muscular atrophy: should we change standards of care? 140
Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report 137
First report of a family with a DMD out of frame exon 2 deletion associated with asymptomatic phenotypes. 136
Teriparatide (rhPTH 1-34) in Duchenne Muscular Dystrophy related osteoporosis: a case report 135
Teriparatide (rhPTH) treatment in Duchenne Muscular Dystrophy, a case report. 135
Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions 135
Practical approach to respiratory emergencies in neurological diseases 135
Espressione di ANT1 e attivazione della via RAGE-NF-kB nella miosite a corpi inclusi. 134
Amyloid myopathy presenting with rhabdomyolysis. 133
Selective short-term verbal memory involvement in two siblings carrying centronuclear myopathy due to DNM2 gene mutations 133
Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle 132
6 min walking test 12 month changes in DMD: Correlation with genotype. 130
Timed rise from floor as a predictor of disease progression in Duchenne muscular dystrophy: An observational study 130
Impaired rotational mechanics and strain revealing subclinical left ventricular dysfunction in children with neuromuscolar disorders: a speckle tracking study 129
study of flavocoxid in ambulant DMD patients. 129
Histological effects of givinostat in boys with Duchenne muscular dystrophy 129
Implication of SIRT1 and its downstream pathways in dystrophic process. 129
Respiratory Emergencies in Neurological Diseases 129
Integrated care of muscular dystrophies in Italy. Part 2. Psychological treatments, social and welfare support, and financial costs 128
Bone quality in Duchenne muscular dystrophy 127
Muscle Fat-Fraction and Mapping in Duchenne Muscular Dystrophy: Evaluation of Disease Distribution and Correlation with Clinical Assessments: A preliminary experience. 122
Telomere shortening and telomere associated proteins in exercised wild type and mdx mice. 122
Pilot study of flavocoxid in ambulant DMD patients. 121
MYH7-related myopathies: Clinical, histopathological and imaging findings in a cohort of Italian patients 119
The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-α activation and ameliorates muscle function and morphology in mdx mice. 119
Dual-echo dual flip angle gradient-echo MRI technique for quantification of muscle fat fraction in Duchenne muscular dystrophy: a new valuable outcome measure. 118
The 6 minute walk test and performance of upper limb in ambulant duchenne muscular dystrophy boys 116
Role of calcineurin/NFAT on muscle regeneration in dystrophic process. 115
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy 115
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 114
Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone 113
Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study 110
Miopatia prossimale in paziente con sindrome di Williams 109
Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy 102
Pilot study of flavocoxid in ambulant DMD patients. 101
The first report of a patient carrying an out-of-frame exon2 deletion in the dystrophin gene and showing a very unusual phenotype. 100
The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study 100
Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study 100
Telomere length in exercised wild type and mdx mice. 100
FSHD and Williams syndrome: the occurrence of two genetic disorders due to heterozygous DNA fragment deletions in the same patient. 95
L'inibizione dei pathway del fattore nucleare-kappaB, delle MAP chinasi e di COX/5-LOX mediante trattamento con flavocoxid migliora la funzione e la morfologia muscolare nel topo mdx: uno studio comparativo con il metilprednisolone 95
Totale 15.228
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.213
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.213
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202138 0 0 0 0 0 0 0 0 0 0 0 38
2021/2022949 10 97 4 64 48 6 94 37 33 91 88 377
2022/20232.391 195 227 125 158 202 197 18 114 1.081 6 57 11
2023/2024724 31 114 35 82 52 174 35 41 5 32 25 98
2024/20253.384 61 45 39 190 91 84 76 640 721 188 537 712
2025/20269.233 471 615 701 677 724 1.858 1.112 1.122 1.202 420 188 143
Totale 19.209